Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma

• DOI: 10.1021/acsami.0c05763
• Publication Date: 2020-04-24T22:32:38Z
• Authors: Qiangqiang Zhao; Jian Li; Bin Wu; Yinghui Shang; Xueyuan Huang; Hang Dong; Haiting Liu; Wansong Chen; Rong Gui; Xinmin Nie
• Keywords: Nanocarriers; Anaerobic glycolysis; Reprogramming; Aptamer

Toxicity and drug resistance caused by chemotherapeutic drugs have become bottlenecks in treating tumors. The delivery of anticancer based on nanocarriers is regarded as an ideal way to solve the aforementioned problems. In this study, a new antilymphoma nanodrug CD20 aptamer-RBCm@Ag-MOFs/PFK15 (A-RAMP) designed constructed, it consists two parts: (1) metal–organic frameworks Ag-MOFs (AM) loaded with tumor aerobic glycolysis inhibitor PFK15 (P), forming core part (AMP); (2) targeted molecule aptamer (A) inserted into red blood cell membrane (RBCm) form shell (A-R). A-RAMP under guidance actively targets B-cell lymphoma both vitro vivo. As result, not only significantly inhibits effect growth but also shows no obvious side effects treated nude mice, indicating that can accurately target cells, reprogram glycolysis, exert synergistic antitumor Ag+ PFK 15. Furthermore, mechanism vivo apoptotic pathway targeting metabonomics are explored. These results suggest has promising application prospect smart, safe, effective, agent.